Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Adjuvant therapy for melanoma
Autore:
Sondak, VK;
Indirizzi:
Univ Michigan, Sch Med, Div Surg Oncol, Comprehens Canc & Geriatr Ctr 3306, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 tr Ctr 3306, Ann Arbor, MI 48109 USA
Titolo Testata:
CANCER JOURNAL
, volume: 7, anno: 2001, supplemento:, 1
pagine: S24 - S27
SICI:
1528-9117(200107/08)7:<S24:ATFM>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESECTED CUTANEOUS MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; STAGE-III MELANOMA; MALIGNANT-MELANOMA; RANDOMIZED TRIAL; INTERFERON ALPHA-2A; METASTATIC MELANOMA; RADIATION-THERAPY; IMPROVED SURVIVAL; PHASE-III;
Keywords:
adjuvant therapy; cutaneous melanoma; interferon; radiation; vaccine therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Sondak, VK Univ Michigan, Sch Med, Div Surg Oncol, Comprehens Canc & Geriatr Ctr 3306, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA Univ Michigan 1500 E Med Ctr Dr Ann Arbor MI USA 48109 8109 USA
Citazione:
V.K. Sondak, "Adjuvant therapy for melanoma", CANCER J, 7, 2001, pp. S24-S27

Abstract

Patients with deep primaries ( greater than or equal to 4 mm) or regional lymph node involvement often require adjuvant therapy in addition to surgery to successfully treat melanoma. Various adjuvant strategies are reviewed. Randomized trials of IFN-alpha adjuvant therapy have demonstrated statistically significant improvements in disease-free and overall survival rates, leading to approval by the United States Food and Drug Administration of the use of I year of intensive IFN-alpha 2b following surgical resection of high-risk disease. A study comparing high-dose IFN with the ganglioside vaccine GMK was terminated early when the Data Safety Monitoring Committee concluded that the high-dose IFN treatment arm was associated with highly significantly improved relapse-free and overall survival. Studies of IFN-alpha in stage I and II melanoma are reviewed. Dose and schedule issues in the useof IFN-alpha are addressed. In addition to adjuvant therapy with IFN-alpha, various other treatment strategies appear promising. Adjuvant vaccine therapy may be useful for treatment of cutaneous melanoma. Polyvalent melanomavaccines are discussed as a potential adjuvant therapy. Finally, nonrandomized preliminary studies suggest that postoperative radiation to the neck or axilla after radical lymph node dissection may decrease regional recurrence rates in node-positive patients, supporting the selective use of radiation therapy for melanoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/02/20 alle ore 11:26:56